

<b>a. Genotypes 16/18 in HPV tests: high vaccine effectiveness against vaccine genotypes</b>			
Test outcome on the 16/18 component	CIN2+ associated with HPV16/18	<CIN2 associated with HPV16/18	Total
Test positive	TP ↓	FP ↓	(TP+FP) ↓
Test negative	FN ↓	TN ↑	(FN+TN) ↑
Total	(TP+FN) ↓	(FP+TN) ↑	N ↔

<b>b. Non-vaccine genotypes in HPV tests: cross-protection against a small number of genotypes</b>			
Test outcome on the non-16/18 component	CIN2+ associated with non-vaccine genotypes	<CIN2 associated with non-vaccine genotypes	Total
Test positive	TP ↓	FP ↓	(TP+FP) ↓
Test negative	FN ↓	TN ↑	(FN+TN) ↑
Total	(TP+FN) ↓	(FP+TN) ↑	N ↔

<b>c. Non-vaccine genotypes in HPV tests: viral unmasking</b>			
Test outcome on the non-16/18 component	Non-vaccine genotypes present	Non-vaccine genotypes not present	Total
Test positive	TP ↑	FP ↔	(TP+FP) ↑
Test negative	FN ↓	TN ↔	(FN+TN) ↓
Total	(TP+FN) ↔	(FP+TN) ↔	N ↔

<b>d. Non-vaccine genotypes in HPV tests: clinical unmasking, misattribution of the causal genotype in pre-vaccination CIN2+</b>			
Test outcome on the non-16/18 component	CIN2+ associated with non-vaccine genotypes	<CIN2 associated with non-vaccine genotypes	Total
Test positive	TP ↑	FP ↓	(TP+FP) ↔
Test negative	FN ↔	TN ↔	(FN+TN) ↔
Total	(TP+FN) ↑	(FP+TN) ↓	N ↔

<b>e. Non-vaccine genotypes in HPV tests: clinical unmasking, reduction in CIN2+ associated with vaccine-preventable genotypes</b>			
Test outcome on the non-16/18 component	CIN2+ associated with non-vaccine genotypes	<CIN2 associated with non-vaccine genotypes	Total
Test positive	TP ↑	FP ↓	(TP+FP) ↔
Test negative	FN ↑?	TN ↓?	(FN+TN) ↔
Total	(TP+FN) ↑	(FP+TN) ↓	N ↔